Continuing Education Online Courses


Browse online courses available for Continuing Education Credit.

Click here to view more online courses and resources for clinicians.

2020 CE Courses
Collapse Refining Patient Selection for Biomarker-Directed Immunotherapy

Access Course

 

As diagnostic and therapeutic advances intersect, there is a significant impact on oncology patient care and increased the use of molecular testing to guide treatment decision-making. While these practices are evidence-based, complex, and incorporated into clinical guidelines, their adoption is fraught with challenges including the multiple companion diagnostic tests associated with immunotherapies. Ask an expert pathologist and oncologist your burning questions as they discuss their strategies for improving molecular testing, which biomarkers to test for, interpreting molecular test results, and how that translates to selecting immunotherapy for patients with solid tumors.

 

This activity is intended for medical, surgical, radiation oncologists and other healthcare professionals (i.e. oncology nurses, physicians’ assistants, pharmacists, and others) interested/involved in the care of patients with cancer, who are being treated with immunotherapy.

 

Learning Objectives:

  • Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
  • Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively

 

Approximate Time to Complete: 60 minutes

 

Credit Available: June 10, 2020 - February 28, 2021

 

Developed through a collaboration between SITC and PlatformQ.

sitc_log_color.png     

logo

 

Original Course Date: June 10, 2020

Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Refining Patient Selection for Biomarker-Directed Immunotherapy
    Collapse Advances in Cancer Immunotherapy™ Webinar — Clinical Updates from ESMO Immuno-Oncology Congress 2019: Claim Credit

    aci17-Online-clr.png

    The SITC Advances in Cancer Immunotherapy™: Clinical Updates from ESMO Immuno-Oncology Congress 2019 Webinar, held on June 9, 2020, is available for continuing education credits. 

     

    Continuing Education Credit Information
    Continuing Education Credits are available for physicians, nurses and pharmacists. To view full accreditation information, click here.

     

    Request Credit

    1. Click the Register Now button.
    2. You will be prompted to log in or create a free account.
    3. Click the Request Credit button.
    4. On the Manage Your Credit screen, follow the instructions to select the Credit Reporting Organization you wish to claim credit for. (Note: For pharmacist completers, enter your NABP# (required).) Then click Continue.
    5. Complete the evaluation. Then click Submit.
    6. On the Confirm All Information screen, verify your Credit Reporting Organization and click Process Credit.
    7. On the Education Credit Profile Screen, scroll down to the Submitted Credit section to view your certificate. 

     

    For Pharmacists: Pharmacists have up to 30 days to complete the online evaluation and claim credit for participation so that information can be submitted to the CPE Monitor as required. 

     

    Target Audience

    The webinar is intended for clinical oncologists, registered nurses, nurse practitioners, advanced practice registered nurses, pharmacists, physician assistants, emergency physicians, allied health professionals, other patient care providers, students and patient advocates.


    Webinar Learning Objectives

    • Describe the latest advances in biomarkers for immune checkpoint inhibitor therapy

    • Explain the impact of adverse event management on cancer outcomes with immune checkpoint inhibitor treatments

    • Summarize emerging therapeutic approaches to increase the efficacy of cancer immunotherapy


    Webinar Faculty

    • Joshua Brody, MD – Icahn School of Medicine at Mount Sinai
    • Ezra Cohen, MD – University of California San Diego
    • Tanja de Gruijl, PhD – VU University Medical Center
    • Geoffrey Gibney, MD – Georgetown Lombardi Comprehensive Cancer Center

     

    On-demand Webinar

    The recorded webinar video and slides will be available here within 24 hours after the webinar concludes.

    (Please note that the on-demand webinars are not available for continuing education credits.) 

     

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png
     

     

    This webinar is supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc. 

    Original Course Date: June 01, 2020

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • CoP: 0.00 hours Certificate of Participation
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Advances in Cancer Immunotherapy™ Webinar — Clinical Updates from ESMO Immuno-Oncology Congress 2019: Claim Credit
    Collapse Immunotherapy for the Treatment of Skin Cancers

    Published May 26, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Skin Cancers, provides the latest in immunotherapy treatment for skin cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancers.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Ryan J. Sullivan, MD
    Assistant Professor of Medicine
    Harvard Medical School, Boston, MA
    Division of Hematology/Oncology, Department of Medicine
    Massachusetts General Hospital, Boston MA

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for skin cancers. 
    • Identify common side effects of immunotherapy agents.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 5/26/20 - 5/26/21

    Approximate Time to Complete:  75 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (.125 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2143-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Ryan J. Sullivan, MD: Consulting Fees (Merck, Novartis, Replimune, Bristol Myers Squibb, Asana Biosciences); Contracted Research (Merck, Amgen)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Skin Cancers.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: May 26, 2020

    Approved Credit:
  • ACPE: 1.25 hours Contact Hour
  • ANCC: 1.30 hours Contact Hour
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Skin Cancers
    Collapse Immunotherapy for the Treatment of Hepatocellular Carcinoma

    Originally published May 26, 2020 (Updated June 9. 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Hepatocellular Carcinoma (HCC), provides an overview of liver immunobiology and immunotherapeutic strategies in HCC, including checkpoint inhibition, blocking inhibitory cytokines, vaccine therapies, oncolytic viruses, and adoptive cell therapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for HCC.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Anuradha Krishnamurthy, MD
    Assistant Professor of Medicine
    University of Pittsburgh School of Medicine
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the characteristics of liver immunobiology
    • Implement cancer immunotherapy treatment for HCC and better manage common side effects
    • Describe the rationale for common approaches to cancer immunotherapy
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 5/26/20 - 5/26/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2142-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Anuradha Krishnamurthy, MD: Nothing to disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hepatocellular Carcinoma.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: May 26, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Hepatocellular Carcinoma
    Collapse Case Studies in Head and Neck Cancer: What Is the Best Sequence of Therapy?

    Access Course

     

    Case Studies in Head and Neck Cancer: What Is the Best Sequence of TherapyThe role of immunotherapy in the treatment of patients with advanced squamous cell carcinoma of the head and neck (SCCHN) is explored through two cases.

     

    The cases presented are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice.

     

    This activity is intended for hematologist/oncologists, surgeons, and other healthcare professionals who treat patients with SCCHN.

     

    The goal of this activity is to increase understanding of current approaches to treating advanced SCCHN with immunotherapy.

     

    Learning Objectives:

    • Have increased knowledge regarding the clinical study designs, as well as efficacy and safety findings, from trials that have evaluated immune checkpoint inhibitor regimens in patients with recurrent or metastatic SCCHN.
    • Have greater competence related to identifying tumor characteristics and other clinical features that guide treatment selection in patients with recurrent or metastatic SCCHN.
    • Have greater competence related to strategies for monitoring and managing treatment-related adverse events.

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: May 15, 2020 - May 15, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" (Published July 15, 2019)

     

     

     

    View Guidelines Here.

    View On-Demand Webinar Here.

     

    Original Course Date: May 15, 2020

    Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Case Studies in Head and Neck Cancer: What Is the Best Sequence of Therapy?
    Collapse Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm?

    Access Course

     

    Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm? Experts discuss the current role of checkpoint inhibition in hepatocellular cancer (HCC) as well as the emergence of combination therapies.

     

    The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of HCC.

     

    This activity is intended for hematologists/oncologists, gastroenterologists, nurses/nurse practitioners, pharmacists, and other healthcare professionals who treat patients with advanced hepatocellular cancer.

     

    Learning Objectives:

    • Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors (ICIs) in managing unresectable HCC.
    • Have greater competence related to identifying when an ICI should be considered for a patient with unresectable/advanced HCC.
    • Have greater competence related to managing immune-related adverse events (irAEs) in patients with unresectable HCC.

     

    Approximate Time to Complete: 45 minutes

     

    Credit Available: May 8, 2020 - May 8, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

     

     

     

     

    View Guidelines Here.

     

    Original Course Date: May 08, 2020

    Approved Credit:
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ANCC: 0.75 hours Contact Hour
  • ACPE: 0.75 hours CEU

  • MORE INFOMORE INFO Immune Checkpoint Inhibitors in HCC: Where Do They Fit in the Treatment Algorithm?
    Collapse Immunotherapy for the Treatment of Head and Neck Cancer

    Originally published April 30, 2020 (updated May 7, 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Head and Neck Cancer, provides an overview of immunotherapy treatment for head and neck cancer. Multiple clinical trials are discussed, including both mono- and combination therapies.  Learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for head and neck cancer.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Michael Gibson, MD, PhD FACP
    Associate Professor of Medicine
    Director of Translational Research for Head and Neck Oncology
    Director of Translational Therapeutics for Esophago-Gastric Oncology
    Vanderbilt-Ingram Cancer Center
    Vanderbilt University Medical Center
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatments for head and neck cancers. 
    • Identify appropriate clinical management of common side effects of immunotherapy agents. 
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 4/30/20 - 4/30/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2066-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Michael Gibson, MD, PhD: Consulting fees to Merck, Bristol-Myers Squibb; Fees for Non-CME/CE services received directly from a commercial interest or their agents to Bristol-Myers Squibb (non-branded)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 4/30/20 through 4/30/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Head and Neck Cancer.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: April 30, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Head and Neck Cancer
    Collapse Test Your Skills: Treating Bladder Cancer

    Access Course

     

     Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices - order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface.

     

    Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

     

    This activity is intended for Hem/Onc specialists, urologists, and emergency medicine specialists.

     

    The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the diagnosis, evidence-based treatment, counseling, and follow-up related to patients with advanced urothelial cancer.

     

    Learning Objectives:

    • Have greater competence related to ordering appropriate testing to determine patient eligibility for therapy in advanced urothelial carcinoma (UC).
    • Have greater competence related to prescribing appropriate therapy in a patient with advanced UC based on patient and disease-specific factors.
    • Have greater competence related to providing appropriate conseling and follow-up for a patient receiving treatment for advanced UC.

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: April 28, 2020 - April 28, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma" (Published August 15, 2017)

     

     

     

    View Guidelines Here.

     

    Original Course Date: April 28, 2020

    Approved Credit:
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Test Your Skills: Treating Bladder Cancer
    Collapse The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial Cancers

    Access Course

     

    The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial CancersRead about the latest advances in immuno-and targeted therapies for treating patients with advanced cervical and endometrial cancers.

     

    This activity is intended for hematologist/oncologists, obstetrics/gynecologists, and other healthcare professionals who treat patients with cervical and endometrial cancers.

     

    The goal of this activity is to increase understanding of current standards and new strategies for the treatment of advanced cervical and endometrial cancers.

     

    Learning Objectives:

    • Have increased knowledge regarding the current standard of care for patients with advanced cervical and endometrial cancers.
    • Have increased knowledge regarding the clinical trial safety and efficacy data for novel therapies, both alone and in combination with other novel agents, in advanced cervical and endometrial cancers.
    • Demonstrate greater confidence in their ability to interpret clinical trial data of novel agents in order to understand the impact on the treatment paradigm in advanced cervical and endometrial cancers.

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: April 10, 2020 - April 10, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: April 10, 2020

    Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO The Evolving Therapeutic Landscapes in Advanced Cervical and Endometrial Cancers
    Collapse Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer

    Access Course

     

    Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer Experts discuss the use of checkpoint inhibitors in the first and second line for advanced urothelial carcinoma as well as future directions.

     

    This activity is intended for oncologists, urologists, emergency department physicians, and other healthcare professionals who treat patients with bladder cancer.

     

    The goal of this activity is to increase understanding in the latest advances in immunotherapy for the treatment of patients with advanced bladder cancer.

     

    Learning Objectives:

    • Have increased knowledge regarding the current role for immune checkpoint inhibitors (ICIs) in the treatment of advanced urothelial carcinoma (UC).
    • Have increased knowledge regarding novel ICIs and novel combination trials in advanced UC.
    • Have greater competence related to incorporating emerging data into clinical practice when managing patients with advanced UC.

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: April 8, 2020 - April 8, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma" (Published August 15, 2017)

     

     

     

    View Guidelines Here.

     

    Original Course Date: April 08, 2020

    Approved Credit:
  • : 1.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Current and Future Role of Immune Checkpoint Inhibitors for the Treatment of Advanced Bladder Cancer
    Collapse Immunotherapy for the Treatment of Genitourinary Malignancies

    Originally published March 31, 2020 (updated May 7, 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for the genitourinary malignancies renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials are discussed, including both mono- and combination therapies.  Learners will have an opportunity to interactively apply what they've learned through three case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for genitourinary malignancies.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Pedro Barata, MD, MSc
    Assistant Professor of Medicine
    Deming Department of Medicine
    Section of Hematology/Oncology
    Tulane University School of Medicine
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatments for genitourinary malignancies. 
    • Identify appropriate clinical management of common side effects of immunotherapy agents. 
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 3/31/20 - 3/31/21

    Approximate Time to Complete:  1 hour
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     


    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2051-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.8 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Pedro Barata, MD, MSc: Consulting Fees (Exelixis, Caris, Bayer, Janssen, EMD-Serono, Pfizer, Astellas, Dendreon, Clovis, Eisai, Sanofi); Contracted Research (BlueEarth Diagnostics, Nektar, AstraZeneca and Seattle Genetics)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 3/31/20 through 3/31/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Genitourinary Malignancies.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: March 31, 2020

    Approved Credit:
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Genitourinary Malignancies
    Collapse Immunotherapeutic Approaches in TNBC: The Latest Data

    Access Course

     

    Immunotherapeutic Approaches in TNBC: The Latest DataDrs Emens and Adams discuss the emerging data for checkpoint inhibition in both the metastatic and neoadjuvant disease settings for TNBC.

     

    This activity is intended for oncologists, obstetricians/gynecologists, and other healthcare professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).

     

    The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of TNBC.

     

    Learning Objectives:

    • Have increased knowledge regarding the biologic rationale for using immune checkpoint inhibitors (ICIs) to manage patients with TNBC.
    • Have increased knowledge regarding the emerging clinical trial data on the use of ICIs in the management of TNBC
    • Have increased knowledge regarding the ongoing clinical trials that may affect standards of care across the treatment continuum for TNBC

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 22, 2020 - Mar. 22, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: March 22, 2020

    Approved Credit:
  • : 0.25 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Immunotherapeutic Approaches in TNBC: The Latest Data
    Collapse Case Studies in Lung Cancer: Test Your Skills

    Access Course

     

    Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices—order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface. Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

     

    This activity is intended for hematologist/oncologist specialists.

     

    The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the diagnosis, biomarker testing, evidence-based frontline treatment, and potential treatment-related adverse events of patients with advanced lung cancer.

     

    Learning Objectives:

    • Select appropriate diagnostic and biomarker tests to guide treatment selection for a patient with advanced lung cancer.
    • Order an appropriate, evidence-based frontline treatment regimen for a patient with advanced lung cancer.
    • Provide patient education for potential treatment-related adverse events.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 18, 2020 - Mar. 18, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Lung Cancer Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: March 19, 2020

    Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Case Studies in Lung Cancer: Test Your Skills
    Collapse Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?

    Access Course

     

    Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?Experts discuss the use of checkpoint inhibition in metastatic melanoma as well as its expansion into the adjuvant setting and beyond.

     

    This activity is intended for oncologists, dermatologists, and other healthcare professionals who treat patients with melanoma.

     

    The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of melanoma.

     

    Learning Objectives:

    • Have increased knowledge regarding the emerging clinical trials data on the use of immune-modulating agents in the management of melanoma
    • Have increased knowledge regarding the place in therapy for immune checkpoint inhibitors in patients with melanoma

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 4, 2020 - Mar. 4, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Melanoma Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma" (Published May 30, 2018)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: March 04, 2020

    Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?
    Collapse What

    Published February 11, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, What's Next for Cancer Immunotherapy?, covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Evan J. Lipson, MD
    Associate Professor, Department of Oncology
    Johns Hopkins University School of Medicine

    Parul Agarwal, MD
    Medical Oncology Fellow
    Johns Hopkins University School of Medicine
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale behind expanding the settings in which cancer immunotherapy is administered, including patients with a larger variety of tumor types and patient populations previously excluded from clinical trial participation.
    • Describe the basis for novel immunotherapy drug combinations.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 2/11/20 - 2/11/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-1083-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Evan J. Lipson, MD: Consultant (Bristol-Myers Squibb, Novartis, EMD Serono, Array BioPharma, Macrogenics, Merck); Contracted Research (Bristol-Myers Squibb, Merck)
     

    Parul Agarwal, MD: Nothing to Disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 2/11/20 through 2/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for What's Next for Cancer Immunotherapy?
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: February 11, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO What
    Collapse Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCC

    Access Course

     

    Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCCWatch experts discuss the latest data in immunotherapy as well as strategies for managing patients with advanced RCC.

     

    This activity is intended for oncologists, urologists, nephrologists, nurses and nurse practitioners, pharmacists, and other healthcare providers who manage patients with renal cell carcinoma (RCC).

     

    The goal of this activity is to increase understanding of the latest advances in the use of checkpoint inhibition in patients with advanced RCC.

     

    Learning Objectives:

    • Have increased knowledge regarding the emerging clinical trial data on the use of immune checkpoint inhibitors (ICIs) and other immunotherapies alone or in combination in the treatment of advanced RCC
    • Have increased knowledge regarding the impact of recent clinical data on the treatment paradigm for patients with advanced RCC
    • Demonstrate greater confidence in their ability to work with the interprofessional team to recognize and mitigate adverse events (AEs) in patients with advanced RCC

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 30, 2020 - Jan. 30, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Lung Cancer Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" (Published December 20, 2019)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: January 30, 2020

    Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.05 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCC
    Collapse Immunotherapy for the Treatment of Hematologic Malignancies

    Originally published January 23, 2020 (Updated May 7, 2020)

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides the latest in immunotherapy treatment for hematological cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for hematologic cancers.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Bhagirathbhai R. Dholaria, MBBS
    Assistant Professor
    Department of Hematology - Oncology
    Vanderbilt University School of Medicine, Nashville, TN
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for hematologic cancers. 
    • Identify common side effects of immunotherapy agents.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 1/23/20 - 1/23/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-1072-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Bhagirathbhai R. Dholaria, MBBS: Celgene (consulting)


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/23/20 through 1/23/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hematologic Malignancies.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: January 23, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.80 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Immunotherapy for the Treatment of Hematologic Malignancies
    Collapse Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCC

    Access Course

     

    Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCCDrs Pal and Hammers discuss data and clinical pearls for the use of checkpoint inhibitors in RCC.

     

    This activity is intended for hematologists/oncologists and urologists.

     

    The goal of this activity is to improve knowledge and competence related to the role of immune checkpoint inhibitors (ICIs) as monotherapy and combination therapy for patients with renal cell carcinoma (RCC).

     

    Learning Objectives:

    • Have increased knowledge regarding the clinical trial data related to ICIs for the treatment of RCC
    • Have greater competence related to selecting patients with RCC who are appropriate candidates to receive ICI therapy

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 21, 2020 - Jan. 21, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" (Published December 20, 2019)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: January 21, 2020

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCC
    Collapse Toxicity Management

    Published January 16, 2020

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Toxicity Management, provides an overview of clinical toxicity management for cancer immunotherapy. Both common and uncommon immune-related adverse events (irAEs) are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to manage immune-related adverse events for patients receiving cancer immunotherapy.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Morgan Gwynn, PharmD, BCOP, CPP
    Melanoma and Head & Neck Oncology Clinical Pharmacist Practitioner
    University of North Carolina Medical Center
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify common and uncommon immune-related adverse events associated with cancer immunotherapy
    • Describe best practices for managing common side effects seen in cancer immunotherapy treatment

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 1/16/20-1/16/21

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-1068-H01-P)

    Type of Activity: Application


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hour.  Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Morgan Gwynn, PharmD, BCOP, CPP: Nothing to disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/16/20 through 1/16/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Toxicity Management.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: January 16, 2020

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.80 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Toxicity Management
    2019 CE Courses
    Collapse Going Beyond PD-(L)1 Inhibition: Where Can Manipulating the Immune System take Cancer Care?

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Learn about agents that target pathways in solid tumors other than PD-1/PD-L1

     

    This activity is intended for hematologists/oncologists, nurses, and pharmacists.

     

    The goal of this activity is to improve knowledge regarding immunotherapy pathways beyond programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1), and data for agents that target these pathways.

     

    Learning Objectives:

    • Have increased knowledge regarding the common strategies and pathways beyond PD-(L)1 that cancer cells harness to avoid detection by the immune system
    • Have increased knowledge regarding the mechanisms of action (MOAs) of emerging cancer immunotherapies
    • Have increased knowledge regarding the scientific rationale for evaluating and integrating cancer immunotherapy throughout the continuum of care for patients with cancer

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 26, 2019 - Dec. 26, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: December 26, 2019

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.05 hours CEU
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Going Beyond PD-(L)1 Inhibition: Where Can Manipulating the Immune System take Cancer Care?
    Collapse Novel Insights Into the Use of Immune Checkpoint Inhibitors in Lung Cancer

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

     

    This activity is intended for hematologists/oncologists, pulmonologists, pathologists, nurses, and pharmacists.

     

    The goal of this activity is to improve knowledge regarding recent clinical trial data on the use of immune checkpoint inhibitors (ICIs) alone or in combination in advanced lung cancers.

     

    Learning Objectives:

    • Have increased knowledge regarding the emerging clinical trial data on the use of ICIs alone or in combination with other cancer immunotherapies in the management of advanced lung cancers
    • Have increased knowlege regarding the impact of recent clinical data on treatment strategies for patients with advanced lung cancers in the community oncology setting

     

    Approximate Time to Complete: 45 minutes

     

    Credit Available: Dec. 26, 2019 - Dec. 26, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: December 26, 2019

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.08 hours CEU
  • ANCC: 0.75 hours Contact Hour

  • MORE INFOMORE INFO Novel Insights Into the Use of Immune Checkpoint Inhibitors in Lung Cancer
    Collapse Mechanisms of Immune-related Adverse Events

    Published December 23, 2019

     

    Course Description

    This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs). The foundational knowledge presented in this course is critical to understanding how and why immune-related adverse events occur and how they can be treated.

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Pradnya Patil, MD, FACP

    Hematology/Oncology Fellow

    Taussig Cancer Institute, Cleveland Clinic


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss the mechanisms of peripheral and central immune tolerance.
    • Describe the biological pathways involved in mediating autoimmune reactions.
    • Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: December 23, 2019 - December 23, 2020

     

    Estimated time to complete activity: 0.5 hour

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

     

    The 2019-2020 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-887-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Pradnya Patil, MD, FACP: Nothing to disclose

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period December 23, 2019 through December 23, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for "Mechanisms of Immune-related Adverse Events." 
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: December 23, 2019

    Approved Credit:
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Mechanisms of Immune-related Adverse Events
    Collapse Basic Principles of Cancer Immunotherapy

    Published December 17, 2019

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
     

    This Basic Principles of Cancer Immunotherapy course covers the basic principles and mechanisms behind cancer immunotherapy.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses, and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Stefani Spranger, PhD
    Assistant Professor of Biology
    Koch Institute for Integrative Cancer Research at MIT
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy
    • Recognize various approaches to cancer immunotherapy including therapeutic vaccine, adoptive cell transfer, cytokines, checkpoint inhibitor modulation, effector antibodies and antibody-drug conjugates

    • Explain the mechanism by which tumors evade the immune system and mechanisms to overcome this immunosuppression

    • List important biomarkers for measuring the immune response


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 12/17/19-12/17/20

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-991-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.3 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Stefani Spranger, PhD: Consulting fees to Venn Therapeutic, Tango, Takeda, Replimune, Ribon, Dragonfly, Merck, Torque; Contracted Research to Takeda, Exelixis


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 12/17/19 through 12/17/20 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Basic Principles of Cancer Immunotherapy.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Firefox, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: December 17, 2019

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Basic Principles of Cancer Immunotherapy
    Collapse Optimizing Outcomes in Melanoma: A Case Challenge

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Apply best practices to the diagnosis and management of patients with melanoma.

     

    This activity is intended for hem/onc specialists, dermatologists, emergency medicine physicians, and nurse practitioners.

     

    The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the work-up, treatment, and follow-up of patients with melanoma.

     

    Learning Objectives:

    • Demonstrate improved performance associated with assessing patients to determine appropriate treatment strategies for melanoma
    • Demonstrate improved performance associated with identifying an appropriate, evidence-based treatment regimen for a patient with melanoma
    • Demonstrate improved performance associated with utilizing an interprofessional team approach to identify and provide patient education around adverse event management in the treatment of melanoma

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: Dec. 13, 2019 - Dec. 13, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma" (Published May 30, 2018)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: December 13, 2019

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Optimizing Outcomes in Melanoma: A Case Challenge
    Collapse Practical Barriers in Cancer Immunotherapy Treatment

    Published December 10, 2019

    Course Description

    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

     

    This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
     

    At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.
     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Amy Schippers, PA-C
    Physician Assistant
    St. Luke's University & Health Network
     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting. 
    • Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.
       

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: 12/10/19-12/10/20

    Approximate Time to Complete:  45 minutes
     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg
     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-983-H04-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
     

    Faculty

    Amy Schippers, PA-C: Nothing to Disclose


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
     

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period 12/10/19 through 12/10/20 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Practical Barriers in Cancer Immunotherapy Treatment.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com

     

     

    Original Course Date: December 10, 2019

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Practical Barriers in Cancer Immunotherapy Treatment
    Collapse The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors

    Access Course

     

    The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?Experts discuss pressing issues related to checkpoint inhibitor use, including irAEs and use in autoimmune disease and organ transplant.

     

    This activity is intended for nurses, nurse practitioners, and other healthcare professionals who treat cancer patients with immune checkpoint inhibitors.

     

    The goal of this activity is to increase understanding of the issues surrounding immune checkpoint inhibitors (ICIs), including the risk for immune-related adverse events (irAEs) and optimal patient/caregiver communication.

     

    Learning Objectives:

    • Have increased knowledge regarding the factors, such as medications and a patient's medical history, that may influence the efficacy of ICIs in patients with cancer
    • Have greater competence related to optimizing communication between the cancer care team and the patient/caregiver related to irAEs, including reporting and identifying toxicities
    • Have greater competence related to applying best nursing practices in the management of irAEs

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 25, 2019 - Nov. 25, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png

     

    Additional Resources from SITC:

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: November 27, 2019

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors
    Collapse Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers

    Access Course

     

    Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers

    The latest advances in immunotherapy for CRC, HCC, and gastroesophageal cancers are explored in these 3 columns.

     

    This activity is intended for oncologists, gastroenterologists, and other healthcare professionals who treat patients with gastrointestinal (GI) cancers.

     

    The goal of this activity is to increase understanding of the advances and challenges of using checkpoint inhibitors in the treatment of patients with GI cancers.

     

    Learning Objectives:

    • Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors (ICIs) alone or in combination in patients with advanced or metastatic GI cancers
    • ICI treatment strategies for patients with GI cancers in the community oncology setting

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: November 27, 2019 - November 27, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: November 27, 2019

    Approved Credit:
  • ACCME: 1 hour AMA PRA Category 1 Credit(s)
  • ABIM: 1 hour ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers
    Collapse Introduction to Immunology – <i>Third Edition</i>

    Course Description

    This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

    introduction_to_Immunology-_third_edition-_thumbnail_image.png

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Christian M. Capitini, MD
    Assistant Professor
    University of Wisconsin Carbone Cancer Center


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system. 

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: October 9, 2019 - October 9, 2020

     

    Estimated time to complete activity: 1 hour

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

     

    The 2019-2020 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-884-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.  Designated for 0.5 pharmacotherapy contact hour for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Christian Capitini, MD: Nothing to disclose


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period October 9, 2019 through October 9, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for "Introduction to Immunology – Third Edition."
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 


    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: October 09, 2019

    Approved Credit:
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Introduction to Immunology – <i>Third Edition</i>
    Collapse 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

    Access the updated course, Immunotherapy for the Treatment of Hematologic Malignancies.

    Immunotherapy for the Treatment of Hematologic Malignancies, is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Please note that continuing education credit for 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) is only available through May 3, 2019.
     

    Course Description

    This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for hematological cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for hematologic cancers and how to identify and manage common side effects of immunotherapy agents.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Faculty
    Naval Daver, MD

    Associate Professor

    University of Texasw MD Anderson Cancer Center

    and

    Christian Capitini, MD

    Assistant Professor

    University of Wisconsin - Madison Carbone Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for hematologic cancers. 
    • Identify the appropriate clinical management of common side effects of immunotherapy agents.

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: May 3, 2019 - May 3, 2020

    Approximate Time to Complete:  30 minutes

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-607-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.

    Faculty
    Naval Daver, MD - Consulting Fees - Pfizer, Otsaka, BMS, Daiichi-SanKyo, Jazz, Abbvie, Novartis and  Contracted Research - Pfizer, BMS, Incyte,Sunesis, Karyopharm, Daiichi-SanKyo, Servier, Genentech, Abbvie, Glycomimetics

    Christian Capitini, MD - Consulting Fee - Nektar Therapeutics


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 30, 2019 through April 30, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Hematological Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: May 03, 2019

    Approved Credit:
  • ACPE: 0.50 hours CEU
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)

    Access the updated course, Immunotherapy for the Treatment of Skin Cancers.

    Immunotherapy for the Treatment of Skin Cancers, is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Course Description

    This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for melanoma and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for melanoma and how to identify and manage common side effects of immunotherapy agents.

     

    Target Audience
    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Faculty
    Isabella Glitza, MD, PhD

    Oncologist 

    University of Texas MD Anderson Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for melanoma.
    • Identify the appropriate clinical management of common side effects of immunotherapy agents.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed.  Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     

     


    Continuing Education Information

     

    Credit Available: May 1, 2019 - May 1, 2020

     

    Approximate Time to Complete:  45 minutes

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.pngPIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-606-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Isabella Glitza, MD, PhD - Research - Bristol Myers Squib


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 24, 2019 through April 24, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: May 01, 2019

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Head and Neck Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of head and neck cancers. The module also includes case studies on immunotherapy for the treatment of head and neck cancers.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Glenn J. Hanna, MD

    Medical Oncologist, Dana-Farber Cancer Institute

    Dana-Farber Cancer Institute 

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy in treatment of head and neck cancer patients
    • Identify the appropriate clinical management of common side effects of immunotherapy agents
    • Implement cancer immunotherapy treatments for Head and Neck cancers

    Continuing Education Information

     

    Approximate Time to Complete: One hour and 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-730-H04-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Glenn J. Hanna, MD: Institutional support from BMS and EMD Serono


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: April 25, 2019

    Approved Credit:
  • ACPE: 1.75 hours CEU
  • ANCC: 1.70 hours Contact Hour
  • ACCME (MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

    Access the updated course, Immunotherapy for the Treatment of Genitourinary Malignancies

    Immunotherapy for the Treatment of Genitourinary Malignancies, is a CME-, CPE-, CNE- and MOC-certified activity.
     

    Course Description

    This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for genitourinary cancer, including kidney, bladder and prostate cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for genitourinary cancer (kidney, bladder and prostate cancers), and how to identify and manage common side effects of immunotherapy agents.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Faculty
    Lauren Harshman, MD

    Assistant Professor and Co-director, Kidney Cancer Program

    Dana-Farber Cancer Institute

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for genitourinary cancers. 
    • Identify the appropriate clinical management of common side effects of immunotherapy agents.

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed.  Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: March 28, 2019 - March 28, 2020

    Approximate Time to Complete:  45 minutes

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-608-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.

    Faculty
    Lauren Harshman, MD - Advisory/Research to Bayer, Exelixis, Genentech, Dendreon/Valient, Pfizer, Medivation/Astellas, Kew Group, Theragene, Corvus, Merck, Bristol-Meyers Squib, Jannsen, Sotio, Takeda, Sanofi, Novartis, Applied Clinical Education, PER


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period March 28, 2019 through March 28, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: March 28, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Basic Principles of Cancer Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Basic Prinicples of Cancer Immunotherapy module covers the basic principles and mechanisms behind cancer immunotherapy.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Theodore F. Logan, MD

    Associate Professor, Medicine

    Indiana University Simon Cancer Center

     

    Learning Objectives 

    At the conclusion of this activy, the participants should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy
    • Recognize various approaches to cancer immunotherapy including therapeutic vaccine, adoptive cell transfer, cytokines, checkpoint inhibitor modulation, effector antibodies and antibody-drug conjugates

    • Explain the mechanism by which tumors evade the immune system and mechanisms to overcome this immunosuppression

    • List important biomarkers for measuring the immune response


    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-727-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.1 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Theodore F. Logan, MD: Consulting - Prometheus Laboratories; Contracted Research - Abbott Laboratories, Abraxix BioSciences, Acceleron Pharma, Amgen, Argos Therapeutics, AstraZeneca, AVEO, BioVex, Breistol-Myers Squibb, Eisai, Lilly, GlaxoSmithKline, Roche, Immatics, Merck, Novartis, Pfizer, Synta, Threshold Pharmaceuticals, Mellennium, TRACON Pharma, Cerulean Pharma, EMD Serono, Prometheus Laboratories, Macrogenics, Peloton Therapeutics, Iovance Biotherapeutics, MedImmune, Dynavax

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section.

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Basic Principles of Cancer Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Melanoma module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of melanoma. The module also includes case studies on immunotherapy for the treatment of melanoma.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Elizabeth Buchbinder, MD

    Instructor, Medicine, Dana-Farber Cancer Institute

    Dana-Farber Cancer Institute

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy in treatment of melanoma patients
    • Identify the appropriate clinical management of common side effects of immunotherapy agents
    • Implement cancer immunotherapy treatments for melanoma
    • Describe clinical efficacy of approved immunotherapies
    • Recognize patient selection criteria for different immunotherapies
    • Identify factors influencing dosing and choice of immunotherapy relative to other therapies for melanoma

     


    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-729-H01-P) 

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.6 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Elizabeth Buchbinder, MD: Consulting Fees - Array Pharmaceuticals; Salary - Sanofi


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

     

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.60 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Lung Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of lung cancer. The module also includes case studies on immunotherapy for the treatment of lung cancer.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Deepa Rangachari, MD

    Instructor, Medicine, Harvard Medical School

    Beth Israel Deaconess Medical Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss the clinical data on the efficacy and mechanism of action of approved therapies

    • Recognize patient selection criteria for approved therapies

    • Describe appropriate dosing and sequencing therapies

    • Identify the appropriate clinical management of common side effects of immunotherapy agents

    •  Implement cancer immunotherapy for the treatment of lung cancers

    • Describe the rationale for common approaches to cancer immunotherapy in treatment of naive NSCLC patients

    • Explain the role of biomarkers associated with response or lack of response to immunotherapy including PD-L1, tumor mutational burden (TMB), and epidermal growth factor receptor (EGFR)


    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.

     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-728-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Deepa Rangachari, MD: No conflict of interest to report.

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Hematologic Malignancies module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of hematologic malignancies. The module also includes case studies on immunotherapy for the treatment of hematologic malignancies.

     

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Nirav Shah, MD

    Assistant Instructor, Medicine

    Medical College of Wisconsin

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy for hematologic malignancies
    • Identify the appropriate clinical management of common side effects of immunotherapy agents
    • Implement cancer immunotherapy for Hematologic Malignancies
    • Become familiar with clinical data on the efficacy and mechanism of action of approved therapies
    • Recognize patient selection criteria for approved therapies
    • Select appropriate dosing and sequencing of approved therapies

     


    Continuing Education Information

     

    Approximate Time to Complete: One hour and 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-731-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Nirav Shah, MD: Consulting fees - Juno Therapeutics, Contracted Research - Lentigen Technology, Ownership Interest - Exelexis, Geron, Oncosec

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 1.75 hours CEU
  • ANCC: 1.70 hours Contact Hour
  • ACCME (MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: What

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The What's Next for Cancer Immunotherapy module covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Christian Capitini, MD

    Assistant Professor, Medicine

    University of Wisconsin Carbone Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Become familiar with clinical data on the efficacy and mechanism of action of approved therapies.

    Continuing Education Information

     

    Approximate Time to Complete: 30 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-734-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Christian Capitini, MD: Consulting Fees - Nektar Therapeutics 

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.50 hours CEU
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: What
    Collapse 2019 Video Series: Practical Barriers in Cancer Immunotherapy (Advances in Cancer Immunotherapy™)

    Access the updated course, Practical Barriers in Cancer Immunotherapy Treatment.

    Practical Barriers in Cancer Immunotherapy Treatment, is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Please note that continuing education credit for 2019 Video Series: Practical Barriers in Cancer Immunotherapy (Advances in Cancer ImmunotherapyTM) is only available through April 25, 2020.


    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Practical Barriers in Cancer Immunotherapy module covers practical barriers to implementing immunotherapy in a community setting (operations and reimbursement).. The module also includes a panel discussion in which experts in the field discuss common challenges they have faced including coverage and reimbursement challenges and adverse event managment.

     

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Ryan Weight, DO, MD

    Assistant Professor

    University of Colorado

     

    Monique Giordana, PharmD, BCOP

    Hematology/Oncology Clinical Pharmacy Specialist 

    Regions Hospital 

     

    Lisa A. Kottschade, APRN, MSN, CNP

    Associate Professor of Oncology/Nurse Practitioner

    Mayo Clinic

     

    Jodi Nordberg

    Billing Operations Manager

    UM Physicians

     

    Sara Smith, PharmD, BCOP

    Oncology Clinical Pharmacist

    University of Minnesota Heath Maple Grove

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.

    Continuing Education Information

     

    Approximate Time to Complete: One hour and 30 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-733-H01-P) 

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.  Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Ryan Weight, DO, MD: Consulting Fees - ACCC, Castle Biosciences, Novartis; Fees for Non-CME.CE Services - Merck; Contracted Research - BMS

    Monique Giordana, PharmD, BCOP: No conflict of interest to report.

    Lisa Kottschade, APRN, MSN, CNP: Consulting Fees - BMS, Array BioPharma

    Jodi Nordberg: Fees for Non-CME/CE Services - Genentech

    Sara Smith, PharmD, BCOP: Consulting Fees - Takeda



    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 1.50 hours CEU
  • ANCC: 1.50 hours Contact Hour
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Practical Barriers in Cancer Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Genitourinary Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpg

    Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

    The Immunotherapy for the Treatment of Genitourinary Malignancies module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of Genitourinary Malignancies. The module also includes case studies on immunotherapy for the treatment of Genitourinary Malignancies.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Lenard J. Appleman, MD, PhD

    Associate Professor of Medicine

    UPMC Hillman Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    1. Describe the rationale for common approaches to cancer immunotherapy for genitourinary malignancies 
    2. Identify the appropriate clinical management of common side effects of immunotherapy agents
    3. Implement cancer immunotherapy for genitourinary malignancies
    4. Become familiar with clincial data on the efficacy of approved therapies
    5. Recognize patient selection criteria for approved therapies
    6. Select appropriate dosing and sequencing of approved therapies (including timing and combination approaches)

    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

     

    (Universal Activity Number - JA4008162-9999-19-732-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Leonard J. Appleman, MD, PhD: Contracted Research - Astellas, BMS, Bayer, Exolius, Merck, Roche

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 17, 2019 through April 17, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

     

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: January 31, 2018

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Genitourinary Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)